Jump to content

Ipsen

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Materialscientist (talk | contribs) at 07:52, 24 October 2023 (Reverted edits by 37.65.12.77 (talk): not providing a reliable source (WP:CITE, WP:RS) (HG) (3.4.12)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

This article is about the biopharmaceutical company. For a list of people with the surname, see Ipsen (surname).

Ipsen
Company typePublic
Euronext: IPN
CAC Mid 60 Component
ISINFR0010259150
IndustryPharmaceutical
Founded1929
FounderHenri Beaufour
HeadquartersBoulogne-Billancourt, France
Key people
Marc de Garidel (Non-executive Chairman)
David Loew (Chief Executive Officer)
ProductsList of medicines
RevenueEUR 2,87 billion (2021)
EUR 1,01 billion (2021)
610,500,000 Euro (2020) Edit this on Wikidata
Number of employees
5,700
Websitewww.ipsen.com

Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on transformative medicines in three therapeutic areas: oncology, rare disease and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.[1][2]

Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in more than 100 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index (2005)[3],.[4] The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.[5]

History

In 1929, Dr. Henri Beaufour founded the Beaufour Laboratories in Dreux. The first product marketed was Romarene, a rosemary-based medicine intended for the treatment of digestive disorders, discontinued from the market in 2011.

In the 1950s and 1960s, Laboratoires Beaufour underwent a phase of expansion. In 1954, the group launched betaine citrate, used in the symptomatic treatment of dyspepsia. Henri Beaufour's two sons, Albert and Gérard Beaufour, joined the company.[5] The group opened a factory in Dreux in 1961,[6] and another in L'Isle- sur-la-Sorgue in 1965. A research center opened in Plessis-Robinson the same year.

In the 1970s and 1980s, Laboratoires Beaufour created a subsidiary, Ipsen (1975), and began to internationalize its activities. In 1976, the company opened a research center in Milford (Massachusetts) in the U.S. In 1977, the group launched Smecta (diosmectite clay, a gastrointestinal bandage and anti-diarrhoeal agent).[6]

In 1983, the group created the Fondation Ipsen under the aegis of the Fondation de France, to encourage exchanges between scientists in the field of life sciences.[7]

In 1986, the group launched Decapeptyl,[6] used to treat certain pathologies influenced by sex hormones, such as prostate cancer, endometriosis, uterine fibroids and early puberty.

In the 1990s, the group diversified its activity and continued its international expansion. In 1990, an industrial center was created in Signes, in the Var department. In 1992, the group opened a subsidiary in China. In 1994, the group launched Dysport (type A botulinum toxin for the treatment of muscle spasms) after acquiring the British company Speywood (then called Porton International).[8] The same year, the group opened a subsidiary in Russia.

In 1995, the group launched Somatuline,[6] used to treat hypersecretion of growth hormones (acromegaly) and in neuro-endocrine tumors, and in 1996, Forlax[6] was launched.

In 2000, after the death of Albert Beaufour, the company was taken over by his children, Anne Beaufour and Henri Beaufour.

In 2003, the company changed its name to Ipsen[9] and in 2005, it was listed on the Paris Stock Exchange[10] on Euronext. In 2004, the company inaugurated a new botulinum toxin production unit in Wrexham (UK). In 2007, the company established a partnership with Galderma for botulinum toxin type A products in aesthetic medicine. In addition, somatuline was granted marketing authorization in the United States for the treatment of acromegaly.

In 2007, Ipsen shares were included in the SBF 120 stock market index.

In 2007, Dysport was granted marketing authorization in the United States for certain indications in therapeutic and aesthetic medicine. Decapeptyl 6-month formulation receives marketing authorization in 9 European countries from the European Medicines Agency.

In 2011, Ipsen announced a new strategy focusing on several areas, including a refocus on specialty medicine, research and development and international development.[3] In 2013, Ipsen acquired the British company Syntaxin, a leader in the engineering of recombinant botulinum toxin11. In 2014, the company participated in the creation of a joint laboratory with the CNRS - Archi-Pex -, the Commissariat à l'énergie atomique et aux énergies alternatives and the University of Rennes1, with the aim of designing and developing hormone peptides.

In 2015, Ipsen inaugurated a research and development center in Cambridge, Massachusetts.[11]

In 2016, Dysport Injection was approved in the United States for the treatment of lower limb spasticity in children aged two years and older.

In 2016, Ipsen licensed cabozantinib from Exelixis, which received marketing authorization the same year for the second-line treatment of advanced renal cell carcinoma. In January 2017, Ipsen announced the acquisition of certain assets of Merrimack Pharmaceuticals, including Onivyde, for the treatment of pancreatic and ovarian cancer.

In 2019, Ipsen acquired Montreal-based Clementia Pharmaceuticals, specializing in rare bone diseases,[12], [13],.[14] Clementia brought a drug candidate, palovarotene, to Ipsen for a rare genetic disease, fibrodysplasia ossificans progressiva (FOP).

In February 2022, Ipsen announced the proposed sale of the Consumer HealthCare (CHC) division after entering into exclusive negotiations with the French laboratory Mayoly Spindler.[15]  In July 2022, Ipsen completed the divestment of the CHC business to Mayoly Spindler.

In August 2022, Ipsen successfully completed the acquisition of Epizyme and its lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor for adults with relapsed or refractory follicular lymphoma (FL), which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020. As part of the transaction, Ipsen also acquired Epizyme's first-in-class, oral SETD2 inhibitor development candidate.

In January 2023, Ipsen announced it would acquire rare disease specialist Albireo for $952m, bringing into its portfolio Bylvay (odevixibat), a non-systemic ileal bile acid transport inhibitor for the treatment of paediatric patients with pruritus in progressive familial intrahepatic cholestasis (PFIC).[16][17]

Financial Data

Financial data in EUR millions
Year 2017 2018 2019 2020 2021
Total sales 1,908.7 2,224.8 2,576.2 2,591.6 2,868.9
Change vs prior year - at actual exchange rates 21.1% 16.6% 15,8% 3.5% 10.7%
Core operating margin 20.8% 29.7% 30,4% 32,0% 35.2%
Employees 5,400 5,700 5,800 5,700 5,700

Shareholding

Ownership of Ipsen's share capital (% of total capital) as of 31 December 2021:

Name % of total capital
Free float 40.47%
Beach Tree 26.03%
Highrock 26.03%
MR Schwabe 4.34%
Treasury shares 1.57%
Finvestan 0.22%
Other registered shareholders 0.84%
Employee 0.33%
Directors (others) 0.17%

Medicines

In Oncology

Cabometyx[18] (cabozantinib) is a tyrosine kinase inhibitor (TKI) used in the treatment of advanced kidney cancer (renal cell carcinoma), liver cancer (hepatocellular carcinoma) in adults previously treated with the medicine sorafenib, as well as in radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) after prior systemic therapy

Decapeptyl[18] (triptorelin) is an analogue of the natural gonadotropin-releasing hormone (GnRH), approved for the treatment of locally advanced metastatic prostate cancer, central precocious puberty (CPP) endometriosis, uterine fibroma, and in-vitro fertilization, and used as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor for women at high-risk of breast cancer recurrence.

Somatuline[18] (lanreotide) is a synthetic (analogue) version of the natural hormone somatostatin, which is found naturally in the human body. Used for the treatment of neuroendocrine tumors (NETs), carcinoid syndrome or acromegaly.

Onivyde[18] (irinotecan liposome injection) is prescribed in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Tazverik (tazemetostat) is a methyl transferase inhibitor of EZH2 (enhancer of zeste homologue 2) used to treat people living follicular lymphoma, which is a cancer of the lymphatic system, as well as epithelioid sarcoma which is a rare, slow-growing type of soft tissue cancer which often begin in the soft tissue under the skin of a finger, hand, forearm, lower leg or foot, and in the abdomen or pelvic area.

These indications are approved under FDA accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

In Rare Disease

Increlex[18] (mecasermin) injection is a prescription medicine used to treat children who are very short for their age because their bodies do not make enough IGF-1. This condition is called primary IGF-1 deficiency.

Sohonos[19] (palovarotene) is an oral investigational, selective retinoic-acid receptor gamma (RARγ) agonist being developed as a potential treatment for people living with the debilitating ultra-rare genetic disorder fibrodysplasia ossificans progressiva (FOP).

In Neuroscience

Dysport[18] (Botulinum toxin) is a prescription medicine used for pathologies characterized by involuntary and uncomfortable muscle contractions (dystonias: blepharospasm, spasmodic torticollis, hemifacial spasm; spasticity: spasticity of the upper or lower limb, dynamic deformation of the equine foot). This drug is also used in aesthetic medicine to temporarily reduce certain wrinkles.

Fondation Ipsen

The Fondation Ipsen pour la recherche thérapeutique, created in 1983 under the aegis of the Fondation de France, supports work in the field of therapeutic research32. In particular is focused on helping improve the lives of patients with rare diseases.[7]

It has contributed to numerous major advances in biological and medical research, organized scientific conferences, and produced literature and content to help patients and the wider community understand rare diseases.

Since 2007, Fondation Ipsen has initiated several series of meetings in partnership with the Salk Institute, the Karolinska Institutet, the Massachusetts General Hospital, the DMMGF (Days of Molecular Medicine Global Foundation), as well as with the journals Nature, Cell and Science. The Fondation Ipsen has published more than 100 books and awarded more than 250 prizes and grants.

In 2021, Fondation Ipsen worked directly with 146 organizations to assess the needs of patients with rare diseases. Fondation Ipsen and Science Magazine organized 9 webinars with the world's leading specialists in rare diseases, as well as policymakers from all over the world.The webinars addressed a variety of essential topics for patients living with rare diseases and their families. The webinars received such a strong response that Science Magazine and the Fondation now co-publish an international magazine for the rare disease community: The Rare Disease Gazette.

References

  1. ^ "Ipsen: A dynamic, fast-growing specialty care powerhouse".
  2. ^ "Ipsen | Evaluate".
  3. ^ a b "Ipsen réussit son virage vers la cancérologie". Les Echos (in French). 11 September 2017. Retrieved 13 December 2022.
  4. ^ "Ipsen, le défi américain". Les Echos (in French). 1 October 2015. Retrieved 13 December 2022.
  5. ^ a b France, Centre (17 February 2015). "Ipsen a engagé plus de 40 millions d'euros d'investissement entre 2012 et 2016". www.lechorepublicain.fr. Retrieved 13 December 2022.
  6. ^ a b c d e Mariette Finet & Elisabeth Hennebert (2021). From Beaufour to Ipsen. Qualibris Edition.
  7. ^ a b "Rare Disease Foundation - Homepage". Fondation Ipsen. Retrieved 13 December 2022.
  8. ^ Nouvelle, L'Usine (10 November 1994). "PharmacieBeaufour-Ipsen s'installe outre-Manche avec PortonConnu pour sa recherche, Porton International va ouvrir au septième groupe pharmaceutique français les marchés britannique et américain. Le ticket d'entrée: 550millions de francs" (in French). {{cite journal}}: Cite journal requires |journal= (help)
  9. ^ Nouvelle, L'Usine (29 May 2003). "Ipsen succède à Beaufour Ipsen" (in French). {{cite journal}}: Cite journal requires |journal= (help)
  10. ^ "IPSEN € 100.40 | Euronext exchange Live quotes". live.euronext.com. Retrieved 13 December 2022.
  11. ^ "Aux États-Unis, Ipsen transfère ses activités de R&D à Cambridge, Massachusetts, en 2014". www.businesswire.com. 26 September 2013. Retrieved 13 December 2022.
  12. ^ "Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion". Reuters. 25 February 2019. Retrieved 13 December 2022.
  13. ^ Bourse, Zone (18 April 2019). "Ipsen boucle son acquisition record du canadien Clementia | Zonebourse". www.zonebourse.com (in French). Retrieved 13 December 2022.
  14. ^ Nouvelle, L'Usine (18 April 2019). "Avec l'acquisition de Clementia, Ipsen se renforce dans les maladies rares" (in French). {{cite journal}}: Cite journal requires |journal= (help)
  15. ^ "Ipsen relève ses objectifs pour 2024 et négocie la vente de son pôle santé familiale". Investir (in French). 11 February 2022. Retrieved 13 December 2022.
  16. ^ Dunleavy, Kevin (9 January 2023). "JPM23: Ipsen scoops up liver disease specialist Albireo for $952M". Fierce Pharma. Retrieved 31 January 2023.
  17. ^ "Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases". Ipsen. Retrieved 31 January 2023.
  18. ^ a b c d e f "Our Products". Ipsen. Retrieved 13 December 2022.
  19. ^ "Research and Development". Ipsen. Retrieved 13 December 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ipsen&oldid=1181632179"